Delivery Order SPE2DB25D3021-SPE2DB25FQZDP
Award Date 8/1/25
Potential Completion Date 8/22/25
Potential Value $8.1K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,118.08, with completion scheduled for August 22, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor within the DLA's medical supply chain. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for Ibrance 75 mg capsules (21-count unit) on July 22, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used in cancer treatment, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the prime contractor, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on July 21, 2025, with an ultimate completion date of August 11, 2025. The contract, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitively awarded procurement from the company's existing pharmaceutical supply agreement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ibrance 75 mg capsules (21-count packages) with a ceiling value of $8,123.96. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award is...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ibrance 125 mg capsules (21-count units). This non-set-aside, competitively awarded contract specifies an ultimate completion date of August 28, 2025, and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for 21 capsules of Ibrance 125 mg, a prescription oncology medication used in cancer treatment. Issued on July 29, 2025, with an ultimate completion date of August 19, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement with no small business restrictions. The place of performance is AmerisourceBergen's corporate office location in...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Ibrance 75 mg capsules. The contract, valued at $15,595.70, has an ultimate completion date of April 10, 2024. AmerisourceBergen Drug Corp previously held an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for...
- This delivery order, awarded July 30, 2025, by the Defense Logistics Agency's Medical Supply Chain to AmerisourceBergen Drug Corp, provides for the supply of Ibrance 75 mg tablets in quantities of seven tablets per unit. The contract, valued at $64,987.24 with a firm fixed price structure, is scheduled for completion by August 20, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a $8,123.96 delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg tablets (7-count packaging) under a firm fixed price contract, with an ultimate completion date of August 8, 2025. This competitively awarded contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication commonly used in cancer treatment, reflecting the federal...